The basis for disease-modifying treatments for Alzheimer's disease: The Sixth Annual Mild Cognitive Impairment Symposium

Alzheimer's and Dementia

Volumn 5, Issue 1, 2009, Pages 66-74

  Duara, Ranjan ^a,b   Barker, Warren ^a   Loewenstein, David ^b   Bain, Lisa ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Independent Science Writer   (United States)

Author keywords

Alzheimer's disease; Amyloid plaques; Disease modifying; Mild cognitive impairment; Neurofibrillary tangles; Non pharmacological treatment; Pharmacological treatment

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; AV 45; AZD 103; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; CLIOQUINOL; FDDNP F 18; FLUORINE 18; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN; LITHIUM; MELATONIN; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOOTROPIC AGENT; PBT 2; PLACEBO; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR CHANGE; BRAIN METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE REHABILITATION; DISEASE COURSE; DISEASE MARKER; DRUG SAFETY; DRUG TOLERABILITY; EPISODIC MEMORY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; INTERPERSONAL COMMUNICATION; MENINGOENCEPHALITIS; MENTAL PERFORMANCE; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; SENILE DEMENTIA; SENILE PLAQUE; SINGLE DRUG DOSE; SOCIAL INTERACTION; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 58049134412     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.10.006     Document Type: Review

References (15)

1. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12 (2006) 801-808 Epub 2006 Jun 11
2. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005) 6990-6995 Epub 2005 May 2
3. Tan Z.S., Beiser A.S., Vasan R.S., Roubenoff R., Dinarello C.A., Harris T.B., et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68 (2007) 1902-1908
4. Jefferson A.L., Massaro J.M., Wolf P.A., Seshadri S., Au R., Vasan R.S., et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 68 (2007) 1032-1038
5. Luchsinger J.A., Reitz C., Honig L.S., Tang M.-X., Shea S., and Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65 (2005) 545-551
6. Luchsinger J.A., Reitz C., Patel B., Tang M.-X., Manly J.J., and Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 64 (2007) 570-575
7. Reitz C., Tang M.X., Manly J., Mayeux R., and Luchsinger J.A. Hypertension and the risk of mild cognitive impairment. Arch Neurol 64 (2007) 1734-1740
8. Harrison J., Minassian S.L., Jenkins L., Black R.S., Koller M., and Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64 (2007) 1323-1329
9. Wilson R.S., Arnold S.E., Schneider J.A., Tang Y., and Bennett D.A. The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry 78 (2007) 30-35 Epub 2006 Sep 29
10. Zhang Y., Schuff N., Jahng G.H., Bayne W., Mori S., Schad L., et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 68 (2007) 13-19
11. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 (2006) 2652-2663
12. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) Feb 20;[Epub ahead of print]
13. Cracchiolo J.R., Mori T., Nazian S.J., Tun J., Potter H., and Arendash G.S. Enhanced cognitive activity-over and above social or physical activity-is required to protect Alzheimer's mice against cognitive impairment, reduce Aβ deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem 88 (2007) 277-294
14. Hillman C.H., Erickson K.I., and Kramer A.F. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci 9 (2008) 58-65
15. Acevedo A., and Loewenstein D.A. Nonpharmacological cognitive interventions in aging and dementia. J Geriatr Psychiatry Neurol 20 (2007) 239-249